The dorsal horn of the spinal cord is a crucial site for pain transmission and modulation. Dorsal horn neurons of the spinal cord express group I metabotropic glutamate receptors (group I mGluRs) that exert a complex role in nociceptive transmission. In particular, group I mGluRs promote the activation of L-type calcium channels, voltage-gated channels involved in short-and long-term sensitization to pain. In this study, we analyzed the role of group I mGluRs in spinal nociceptive transmission and the possible cooperation between these receptors and L-type calcium channels in the pathophysiology of pain transmission in the dorsal horn of the spinal cord. We demonstrate that the activation of group I mGluRs induces allodynia and L-type calcium channel-dependent increase in nociceptive field potentials following sciatic nerve stimulation. Surprisingly, in a model of persistent inflammation induced by complete Freund's adjuvant, the activation of group I mGluRs induced an analgesia and a decrease in nociceptive field potentials. Among the group I mGluRs, mGluR1 promotes the activation of L-type calcium channels and increased nociceptive transmission while mGluR5 induces the opposite through the inhibitory network. These results suggest a functional switch exists in pathological conditions that can change the action of group I mGluR agonists into possible analgesic molecules, thereby suggesting new therapeutic perspectives to treat persistent pain in inflammatory settings.
Introduction
The role of glutamate as a major excitatory neurotransmitter in spinal nociceptive integration is well established. 1 Glutamatergic activity is mediated by two types of receptors: ionotropic (iGluRs) and metabotropic (mGluRs) receptors. While ionotropic receptors mediate fast excitatory postsynaptic components, mGluRs are coupled to G-protein and mediate long-term changes in nociceptive transmission. The mGluRs are divided into three groups (I, II, and III) based on pharmacology, signal transduction, and sequence homology. 2 In the dorsal horn (DH) of the spinal cord, neuroanatomical and immunohistochemical studies suggest that group I mGluRs are predominantly localized on postsynaptic elements 3 and are involved in the nociceptive transmission. 4, 5 Indeed, the activation of group I mGluRs increases the excitability of deep dorsal horn neurons (DHNs) in the rat 6 and promotes long-term plasticity. 7 In addition, intrathecal delivery of group I mGluRs agonists induces mechanical and thermal (hot or cold) hypersensitivity as well as spontaneous nocifensive behavior in naive animals. 8, 9 Similar to group I mGluRs, L-type voltage-gated calcium channels are expressed in the DH and are mainly localized on postsynaptic elements. 10, 11 LTCs are involved in nociceptive transmission by controlling the short-and long-term plasticity of DHNs. [12] [13] [14] [15] Finally, it has long been demonstrated that plateau potentials, a mechanism of input/output amplification expressed in deep DHNs, depends on LTCs and is controlled by agonists of mGluRI. 6, [16] [17] [18] In the present study, we analyze the involvement of group I mGluRs and LTCs in nociceptive transmission. We show that in naı¨ve animals, group I mGluRs and LTCs cooperate to amplify nociceptive transmission, whereas in a persistent pain model, group I mGluRs mediate a decrease in nociceptive transmission mediated by the action of subtype mGluR5 on the DH inhibitory network.
Material and methods
Animals. Adult male Sprague Dawley rats (250-350 g) were used in all experiments. Animals were fed and watered ad libitum and kept on 12 h dark/light cycle at room temperature (22 C) with constant humidity. All surgical and experimental protocols were approved by the local ethics committee (ethical approval N #3765) and conformed to the guidelines of the International Association for the Study of Pain. All efforts were made to minimize the number of animals used and their suffering.
Pain behavior. Mechanical threshold of the nociceptive hind paw withdrawal reflex was measured with a Von Frey electronic device (Bioseb, France). Briefly, rats were individually placed in a cage on a mesh floor. After a 10-min habituation period, constantly increasing pressure was applied to the plantar surface of the hind paw until the animal withdrew its paw. The force applied at the time of withdrawal was recorded, and the response was expressed in grams. Each value was the average of five different stimulations 2-min apart to avoid sensitization of the paw. All behavioral experiments were performed in the morning between 10 a.m. and 12 a.m. All behavioral tests were assessed by the same experimenter blind to the group assignment.
Intrathecal injections. Under isoflurane anesthesia, animals were placed on a cylindric roller to curve the spine. Then, 10 mL (10 mM) of (1S,3R)-ACPD was administered intrathecally with a Hamilton syringe between the L5 and L6 vertebrae. The quality of each injection was ensured by the observation of an injection-induced slight tail-flick reflex. All behavioral tests were blinded. Saline (same volume) was used for control injections.
Field potential recordings. Animals were deeply anesthetized with urethane 20% (1.5 g/kg) administered in a single intraperitoneal injection to induce and maintain anesthesia during the electrophysiology recordings. The experiment was started as soon as there was no longer any reflex. The heat rate was monitored during the experiment. Experiments were stopped when a 10% decrease in heat rate was observed. Colorectal temperature was kept at $37 C with a heating blanket. Two metal clamps were used to set the animal spine in a stereotactic frame (M2E, France) for stability during electrophysiological recordings. Then, a laminectomy was performed at T13-L1 to expose the lumbar part of the spinal cord. The dura mater was removed carefully. A vaseline pool was formed around the exposed spinal segments to ensure that no drug was administered beyond the area of interest. Drugs were applied with a syringe pump (Phymep France). C-fiber-evoked field potentials were recorded in deep lamina of the DH (at a depth range 500 and 1000 mm
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) with tungsten microelectrodes (impedance 5 MV). Field potentials were recorded with an ISO-DAM-amplifier (low filter: 0.1 Hz to high filter: 0.1 kHz) (World Precision Instruments, USA) in response to electrical stimulation of the ipsilateral sciatic nerve.
The right sciatic nerve was exposed and placed above the two stimulation electrodes. To avoid drying out, the sciatic nerve was covered with paraffin oil. Electrical stimulation was delivered to the sciatic nerve and consisted of single pulses of 0.5 ms duration, at a constant voltage intensity (range: 20-50 V) twice the threshold of onset of C-fiber-evoked field potentials using a master 8 stimulator (AMPI, Israel) connected to an isoflex stimulus isolator (AMPI, Israel). During the experiment, electrical stimulation was applied every 2 min. The C-fiber response can easily be distinguished by its threshold and latency (100-200 ms 19 ). Stable responses of field potentials for half an hour served as control before drug application. Amplitudes of C-fiber-evoked field potentials were measured as the area under the curve in the C-mediated part of the response, i.e., 150 to 300 ms from the stimulation artifact. The average of the first 30 min before drug application was used as the control value, and responses were normalized to it. The mean change during the last 30 min of drug application was used for statistical analysis.
Inflammatory pain model. Inflammation was induced by a subcutaneous injection of 100 ml of complete Freund's adjuvant (CFA; Sigma Aldrich, Saint Louis, MO) into the dorsal surface of the right ipsilateral hind paw under anesthesia (Vetflurane at 5% for induction and at 2% for maintenance). Control rats received the same volume of 0.9% saline. CFA treatment led to inflammation of the injected paw. A mechanical allodynia was observed from the first day following injection and lasted at least four days. Electrophysiological, biochemical, and behavioral experiments were performed four days after CFA or saline injection.
Drugs. In this study, drugs were applied either directly above the spinal cord during electrophysiology recordings or intrathecally for behavioral tests. Drugs were diluted in saline 0.9% from stock solution and stored at À20
C. Drugs used were group I mGluRs agonist: (1S,3R)-1-amino-cyclopentane-1,3-dicarboxylic acid ((1S,3R)-ACPD, 100 mM, Sigma Aldrich), nifidipine: L-type Ca 2þ channel blocker (100 mM, Tocris, Bristol, UK), mGluR5 antagonist: 2-methyl-6-(phenylethynyl)-pyridine (MPEP; 100 mM, Tocris), mGluR5 agonist: 2-Chloro-5-hydroxyphenylglycine (CHPG; 100 mM, Tocris), GABA-A receptor antagonist: picrotoxin (10 mM, Sigma Aldrich), and glycinergic receptor antagonist: strychnine (5 mM, Sigma Aldrich).
Tissue preparation. To quantify messenger RNA (mRNA; real-time quantitative polymerase chain reaction (qRT-PCR), see below) and protein levels (Western blot, see below) in the DH, rats were deeply anesthetized with pentobarbital sodium at 150 mg/kg. They were then decapitated, and the lumbar spinal cords were removed. Ipsilateral side of the spinal cord was separated from the contralateral side, and then DH was isolated. Ipsilateral and contralateral DH were then isolated and rapidly frozen in dry ice and stored at À80 C. 
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Statistical analysis
Statistical analyses were performed using the GraphPad Prism software (GraphPad Software ß, San Diego, CA). A p value <0.05 was considered significant.
Results
Intrathecal (1S,3S)-ACPD injection produces a mechanical allodynia in control condition
Group I mGluRs agonists are known to promote nociception. We therefore first assessed the consequence of 
Effect of (1S,3S)-ACPD induces an increase in C-fiber-evoked field potentials in control condition
To test whether the decrease in paw withdrawal threshold induced by the activation of group I mGluRs was due to central changes in DH nociceptive transmission, we measured C-fiber-evoked field potentials in the spinal DH of anesthetized adult rats. Potentials were evoked by electrical stimulation of the sciatic nerve with single test pulses. After 30 min of saline superfusion, a solution of (1S,3S)-ACPD was applied at the recording site. (1S,3S)-ACPD induced a significant increase in C-fiber-evoked field potentials 30 min after the drug application (Figure 2 
Increase in paw withdrawal threshold induced by (1S,3S)-ACPD in inflamed paw
Intraplantar injection of CFA in the right paw of the animal led to an ipsilateral hypersensitivity characterized at four days postinjection by a marked lower paw withdrawal threshold in the inflamed paw than in the contralateral paw (Figure 3 (1S,3R)-ACPD induces a decrease in C-fiber-evoked field potentials independently from LTCs following inflammation
After CFA injection, the inflamed paw withdrawal threshold was differently modulated by group I mGluR agonists. We next wondered whether nociceptive transmission in the DH was also affected. Indeed, (1S,3R)-ACPD produced a significant decrease in C-fiber-evoked field potentials (Figure 4(a) and (d) ; the percentage of change in C-fiber-evoked field potentials was À18.21 AE 6.23%, n ¼ 7, p < 0.05, Wilcoxon signedrank test). These results show that the modulation of nociceptive transmission by group I mGluRs agonists depends on the pathophysiological context, suggesting a plasticity group I mGluRs in the DH after inflammation. We next wanted to know whether the inhibition induced by (1S,3R)-ACPD was dependent on LTCs.
To this end, we applied (1S,3R)-ACPD and nifedipine concomitantly. C-fiber-evoked field potentials were decreased in the presence of nifedipine, suggesting that the inhibitory effect of group I mGluRs agonist in an inflammatory setting was independent of LTCs ( Figure 4 Inflammation induced a switch from mGluR1 to mGluR5 sensitivity to (1S,3R)-ACPD Group I mGluRs include mGluR1 and mGluR5. We hypothesized that peripheral inflammation alters mGluR5 expression. Indeed, mGluR5 is a well-known peripheral receptor involved in changes induced by different pain models. To check this hypothesis, we used qRT-PCR to measure the change in mGluR5 mRNA in the DH. We compared the levels of mRNA expression in both saline and CFA animals and compared the ipsilateral and contralateral parts of the DH. Inflammation did not alter mGluR5mRNA expression ( Figure 5(a) , p > 0.05, n ¼ 6, Test de Fisher þ Student's test, Figure  5 (a)). Therefore, we assessed the possibility of posttranslational modification at the protein level. To this end, we used Western blot to compare the level of mGluR5 proteins in the ipsilateral DH of saline and CFA animals. We observed a significant increase in mGluR5 protein levels in the ipsilateral part of the DH in CFA animals as compared to saline ones ( Figure 5(b) , 41.7 AE 10.25% of increase in protein expression in inflammatory condition, p ¼ 0.0096, Wilcoxon signed-rank test, n ¼ 6). We then assessed whether a change in mGluR5 protein level could account for the inhibition of C-fiber field potentials induced by (1S,3R)-ACPD in inflammation.
mGluR5 mediates a decrease in C-fiber-evoked field potentials following inflammation
To test whether this upregulation influences nociceptive transmission, we applied CHPG, a specific agonist for mGluR5 receptors. CHPG produced a significant decrease in C-fiber-evoked field potentials in the inflammatory condition (Figure 6 (a) and (d); the percentage of change in C-fiber-evoked field potentials was À28.49 AE 6.18%, n ¼ 9, p < 0.01, Wilcoxon signed-rank test). By contrast, MPEP, an antagonist of mGluR5, had no effect on C-fiber-evoked field potentials ( Figure 6(d) , À11 AE 6%, n ¼ 8, p ¼ 0.14, Wilcoxon signed-rank test).
Finally, MPEP prevented the decrease in C-fiberevoked field potentials in the presence of (1S,3R)-ACPD ( Figure 6 (b) and (c); the percentage of change in C-fiber-evoked field potentials was À4.77 AE 3.59%, n ¼ 6, p ¼ 0.25, Wilcoxon signed-rank test). These results demonstrate that the decrease in C-fiber-evoked field potentials induced by (1S,3R)-ACPD is mediated by the activation of mGluR5.
(1S,3R)-ACPD-induced antinociceptive effect in ipsilateral DH is mediated by local inhibitory network
Within the spinal cord, the GABA-A and glycine receptors are the two main inhibitory receptors and their activation is crucial for controlling nociceptive transmission. We therefore sought whether the mGluR5 present in inhibitory interneurons could mediate the inhibitory effect of (1S,3R)-ACPD in inflammation. To this end, we blocked inhibition in inflamed rats by applying strychnine and picrotoxin, which inhibit the glycine and GABA-A receptors, respectively, during the application of (1S,3R)-ACPD. Blockade of the inhibitory transmission prevented the decrease in C-fiber-evoked field potentials induced by (1S,3R)-ACPD ( Figure 6(c) ; the percentage of change in Cfiber-evoked field potentials was 2.05 AE 7.04%, n ¼ 7, p ¼ 0.77, Wilcoxon signed-rank test). However, (1S,3R)-ACPD did not induce an increased C-fiber-evoked field potential suggesting a decrease of mGluR1 influence following inflammation. This demonstrates that the increase in mGluR5 in inflamed rats mediated inhibition of C-fiberevoked field potentials via inhibitory interneurons in the DH.
mGluR5-dependent inhibition is insufficient to counterbalance the mGluR1-mediated potentiation of C-fiber-evoked field potentials in control rats
Finally, we sought whether C-fiber-evoked field potentials were inhibited in control rats. As in inflamed rats, CHPG produced a decrease in C-fiber-evoked field potentials (Figure 7 (a) and (c); the percentage of change in Cfiber-evoked field potentials was À21.31 AE 5.77%, n ¼ 11, p < 0.01, Wilcoxon signed-rank test). Finally, to confirm that mGluR5 is not involved in the potentiation of C-fiber-evoked field potentials, we blocked mGluR5 with MPEP and applied (1S,3R)-ACPD. (1S,3R)-ACPD produced an increase in C-fiber-evoked field potentials in the presence of MPEP (Figure 7 (b) and (c); the percentage of change in C-fiber-evoked field potential was 33 AE 14.2%, n ¼ 10, p ¼ 0.01, Wilcoxon signed-rank test). These results showed that in control conditions, mGluR5 mediated inhibition of C-fiber-evoked field potentials, but this inhibition was too weak to reverse the potentiation induced by the activation of mGluR1 with (1S,3R)-ACPD. This strongly suggests that the increase in mGluR5 protein levels in inflamed conditions masked the potentiation of C-fiber-evoked field potentials induced by (1S,3R)-ACPD via mGluR1.
Discussion
The present study investigated the consequence on nociceptive transmission of activating group I mGluRs. We particularly examined the putative cooperation between group I mGluRs and LTCs in the pathophysiology of pain transmission in the DH. We show that inflammation deeply modifies the relative contribution of group I mGluRs to agonist application. The activation of mGluR1 exerts a pronociceptive role in the DH through the activation of LTCs, while mGluR5 exerted an antinociceptive action through the local inhibitory network in the conditions of inflammation (Figure 8 ).
Activation of Group I mGluRs increases nociception via LTCs
By using pain behavior measurements and in vivo electrophysiology, we confirm that the spinal administration of (1S,3R)-ACPD induces an increase in nociceptive transmission. 21 Indeed, intrathecal injection of (1S,3R)-ACPD induced a bilateral decrease in the mechanical paw withdrawal threshold, i.e., a mechanical allodynia. Moreover, spinal application of (1S,3R)-ACPD led to a significant increase in C-fiber-evoked field potentials, thus confirming the spinal action of (1S,3R)-ACPD. These results are in accordance with previous results showing that (1S,3R)-ACPD increases acute hyperalgesia induced by ionotropic glutamate modulators. 22 They are also in line with studies showing that group I mGluRs agonists elicit an increase in the excitability of DHNs. 23, 24 Group I mGluR is also involved in the longterm potentiation of C-fiber nociceptive field potentials, a spinal mechanism of hypersensitivity. 25, 26 (1S,3R)-ACPD applied to the DH increases the amplitude of the windup of spinal neurons, a form of short-term sensitization to pain that is considered to be an indicator of central sensitization to pain. 24 By contrast, this windup is blocked by group I mGluRs antagonists. Moreover, (1S,3R)-ACPD increases the amplitude of plateau potentials that sustain the expression of windup. 6, 18 Both long term potentiation (LTP) and windup depend on the expression of LTCs, which are crucial for neuronal excitability within the DH. 12, 14, 15, 27 Here, we show that LTCs mediate the pronociceptive effect of (1S,3R)-ACPD. We also confirm that LTCs alone do not modify acute pain transmission. 12, 28 This increase in the level of activation of LTCs by group I mGluRs agonist has been well demonstrated in both the dorsal and ventral horn of the spinal cord. 18, 29 Moreover, this effect is mainly mediated by the subtype mGluR1. 6 In our conditions, the pronociceptive effect of group I mGluRs agonist acting through LTCs was not suppressed by the mGluR5-specific antagonist, suggesting that (1S,3R)-ACPD acts via the subtype mGluR1. In conclusion, our results strongly suggest that (1S,3R)-ACPD elicits an increased nociception via the activation of LTCs in DHNs. However, mGluR1 and LTCs are also expressed in afferent nociceptive C-fibers, and we cannot exclude that this peripheral pathway also participate in controlling nociceptive transmission in the DH (Figure 8) .
One of the possible mechanisms of this direct facilitating effect of mGluR1 on LTCs is the phospholipase C (PLC)-IP3 (inositol triphosphate) cascade, which leads to the release of calcium from the intracellular stores that binds to calmodulin, leading to the activation of LTCs, as previously demonstrated. [29] [30] [31] Group I mGluRs may also have an indirect positive effect on LTCs by inhibiting inward rectifier potassium channels that induce membrane depolarization necessary for the activation of LTCs. 18, 32 mGluR5-dependent decreases in nociception induced by group I mGluRs agonists in persistent inflammation Activation of group I mGluRs by (1S,3R)-ACPD reduces spinal nociceptive transmission following CFAinduced inflammation, suggesting a functional change in the expression and/or distribution of the receptors activated by (1S,3R)-ACPD under these pathological conditions. Indeed, intrathecal injection of (1S,3R)-ACPD had an antinociceptive action and decreased the nociceptive field potentials induced by electrical stimulation, specific to the inflamed paw. Such an opposite effect of group I mGluRs agonists under pathophysiological states has already been observed in the excitability of DHNs following intrathecal injection of carrageenan. We show here that this antinociceptive effect of (1S,3R)-ACPD depends on mGluR5 activation. Indeed, after inflammation, we observed a significant increase in mGluR5 protein expression in the ipsilateral DH, a decrease in nociceptive field potential amplitudes following application of mGluR5 agonist, and a lack of effect of (1S,3R)-ACPD when a mGluR5 antagonist was applied. These results are in agreement with previous studies that showed a dose-dependent inhibition of the spinothalamic tracts with a specific agonist of mGluR5. 5 This is surprising given that mGluR5 has been described as being pronociceptive. Indeed, blockade of mGluR5 with the specific antagonist MPEP decreased hypersensitivity induced by partial nerve ligation or carrageenan injection. 34 This pronociceptive role is due to the activation of peripheral mGluR5 rather than spinal ones. [34] [35] [36] Therefore, we cannot rule out the spatial and functional segregation of mGluR5. Finally, a recent study emphasized the role of intracellular mGluR5 in the DH in a mononeuropathy model. While it is unlikely that these receptors were activated in our conditions, 37 we cannot rule out the possibility that our results are specific to the persistent inflammatory model we used. Finally, our findings demonstrate that under persistent inflammation, group I mGluRs agonists have a prominent spinal antinociceptive effect via activation of mGluR5.
mGluR5-dependent decreases in nociception mediated by spinal inhibitory network
The activation of group I mGluRs has been shown to facilitate both inhibitory and excitatory neurotransmission in the DH. 38 However, nothing is known about a putative cellular segregation of the two mGluR subtypes in this site. We show here that the pronociceptive role of mGluR agonists depends on mGluR1 while antinociception is mediated by mGluR5. Moreover, in the context of persistent inflammation, mGluR5 protein expression is increased, and group I mGluR agonists produce antinociception. Finally, we also show that this effect is blocked by blockade of the local inhibitory network. Therefore, it is likely that mGluR5 is localized on inhibitory interneurons that produce this inhibition of nociceptive transmission (Figure 8) . We cannot exclude a decrease of mGluR1 influence in the context of inflammation since group I mGluR agonists did not induce an increase in C-fiberinduced field potentials even under inhibitory network blockade. By contrast, in control conditions, levels of mGluR5 might not be sufficient to overcome the main pronociceptive action of mGluR1. This antinociceptive effect of mGluR5 under persistent inflammation is independent of LTCs, suggesting that mGluR5 acts via other intracellular machinery (Figure 8 ).
Concluding remarks
In summary, we show in this study that the same group I mGluRs agonist exerts an opposite action on spinal nociceptive transmission depending on the pathophysiological state. In control conditions, a pro-nociceptive action mediated by mGluR1 was obtained via activation of LTCs, while in a setting of persistent inflammation; an mGluR5-dependent anti-nociceptive action was evidenced. The findings also suggest that the mGluR subtypes have a different spatial distribution, mGluR5 being localized on the inhibitory interneurons while mGluR1 is potentially present on both the C-fibers and the relay neurons expressing LTCs. In a context where mGluR5 blockers could potentially be used to treat neuropathic pain patients, our findings have important therapeutic implications since understanding of the origin of pain syndromes is crucial for the appropriate pharmacological management of pain.
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